Literature DB >> 15986871

High rate of seropositivity of Chlamydia pneumoniae IgA in male patients with nonalcoholic steatohepatitis.

Fusun F Bolukbas1, Cengiz Bolukbas, Fadile Zeyrek, Mehmet Aslan, Halil I Bahcecioglu, Ilyas Ozardali.   

Abstract

The aim of this study was to investigate if there was any relationship between nonalcoholic steatohepatitis and the rate of Chlamydia pneumoniae seropositivity in a male population. Fifteen men with nonalcoholic steatohepatitis and 20 healthy men were enrolled in the study. The seropositivity rate of Chlamydia pneumoniae immunoglobulin A in the nonalcoholic steatohepatitis and control groups was 53.3 and 5%, respectively. The rate of Chlamydia pneumoniae immunoglobulin A positivity was significantly higher in the nonalcoholic steatohepatitis group than the controls (P = 0.002), while such a difference did not occur for Chlamydia pneumoniae immunoglobulin G positivity (P > 0.05). There is an association between nonalcoholic steatohepatitis and persistent Chlamydia pneumoniae infection as a probable causative or triggering agent. These findings suggest that further studies are necessary to clarify this association.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986871     DOI: 10.1007/s10620-005-2721-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

3.  Antibiotic therapy in coronary heart disease--where do we currently stand?

Authors:  V Anand; S Gupta
Journal:  Cardiovasc Drugs Ther       Date:  2001       Impact factor: 3.727

4.  Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis.

Authors:  M Leinonen; P Saikku
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

Review 5.  Epidemiology of Chlamydia pneumoniae in atherosclerosis.

Authors:  P Saikku
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

Review 6.  Mitochondria in steatohepatitis.

Authors:  D Pessayre; A Berson; B Fromenty; A Mansouri
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

7.  Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis.

Authors:  A Laurila; A Bloigu; S Näyhä; J Hassi; M Leinonen; P Saikku
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Chlamydia pneumoniae DNA is more frequent in advanced than in mild atherosclerosis lesions.

Authors:  Ahmad Reza Bahrmand; Moslem Bahadori; Abdolmajid Hossaini; Ali Akbar Velayati; Sohrab Aghabozorgy; Abbass Shakoor; Valery Vladimir Bakayev
Journal:  Scand J Infect Dis       Date:  2004

10.  Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells.

Authors:  A Casini; M Pinzani; S Milani; C Grappone; G Galli; A M Jezequel; D Schuppan; C M Rotella; C Surrenti
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

View more
  2 in total

1.  Chlamydial and periodontal pathogens induce hepatic inflammation and fatty acid imbalance in apolipoprotein E-deficient mice.

Authors:  Kati Hyvärinen; Anita M Tuomainen; Saara Laitinen; Igor L Bykov; Liisa Törmäkangas; Kai Lindros; Reijo Käkelä; Georg Alfthan; Irma Salminen; Matti Jauhiainen; Petri T Kovanen; Maija Leinonen; Pekka Saikku; Pirkko J Pussinen
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

Review 2.  Infections at the nexus of metabolic-associated fatty liver disease.

Authors:  Robim M Rodrigues; Tamara Vanhaecke; Joost Boeckmans; Matthias Rombaut; Thomas Demuyser; Baptist Declerck; Denis Piérard; Vera Rogiers; Joery De Kock; Luc Waumans; Koen Magerman; Reinoud Cartuyvels; Jean-Luc Rummens
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.